| Acute Myelogenous Leukemia |
ACTRN12613000358741: Azacitidine use in elderly patients (over 65) with high risk myelodysplasia/acute myeloid leukaemia. |
|
|
| Not yet recruiting | 4 | 40 | | | Illawarra Private Cancer Care Centre, Southern Haematology and Cancer Research Institute | myelodysplasia, acute myeloid leukaemia | | | | |
ChiCTR-OPC-15006896: The clinical study of initial induced remission failure in elderly patients with acute myeloid leukemia treated by HCAG/IA in combination with decitabine |
|
|
| Not yet recruiting | 4 | 50 | | D-IA ;D-HCAG | Rui Jin hospital affiliated to Shanghai Jiaotong University School of Medicine, Shanghai Institute of Hematology; Rui Jin hospital affiliated to Shanghai Jiaotong University School of Medicine, QILU pharmaceutical co.,Ltd. | acute myeloid leukima | | | | |
| Completed | 4 | 600 | | HAA regimen: Hom 2mg/m2 im or ivgtt qd day 1-7, Acla 20mg ivgtt qd day 1-7, Ara-C 100 mg/ m2 ivgtt, day 1-7 ;HAD regimen: Hom 2mg/m2 im or ivgtt qd day 1-7 DNR 40mg/m2 iv qd day 1-3 Ara-C 100mg/m2 ivgtt, day 1-7 ;DA regimen: DNR 40 mg/ m2 iv qd day1-3; Ara-C 100 mg/ m2 ivgtt, day 1-7 | Ruijin Hospital affiliated to Shanghai Jiaotong University Medical College; The Ministry of Science and Techonology of the People’s Republic of China, The Ministry of Science and Techonology, China | Acute myelocytic leukemia (AML) | | | | |
ChiCTR-TNC-12001999: Clinical study of decitabine together with aclacinomycin/cytarabine to treating patients with refractory acute myeloid leukemia |
|
|
| Completed | 4 | 20 | | Aclacinomycin /Cytarabine (AA) | Shanghai Sixth People‘s Hospital; Shanghai Sixth People‘s Hospital, research funding | refractory/relapsed de nove or myelodysplastic syndrome (MDS) transformed acute myeloid leukemia (AML) | | | | |
ChiCTR-TRC-11001475: FA regimen as the consolidation chemotherapy in treatment of acute myeloid leukemia (AML): a multi-center, randomised clinical trial |
|
|
| Completed | 4 | 360 | | Fludarabine 30mg/ m2, intravenously administration daily for 3 days; Cytarabine 2g/ m2,intravenously administration daily for 3 days, 6 cycles in total ;Fludarabine 30mg/ m2, intravenously administration daily for 5 days; Cytarabine 1g/ m2,intravenously administration daily for 5 days, 6 cycles in total ;Fludarabine 30mg/ m2, intravenously administration daily for 5 days; Cytarabine 2g/ m2,intravenously administration daily for 5 days, 4 cycles in total | Chinese anti-cancer association; Chinese anti-cancer association, self-funding | acute myeloid leukemia (AML) | | | | |
| Completed | 4 | 100 | | cytarabine (25mg/d, days1-14) and homoharringtonine (1mg/d, days1-14) by intravenous continuous infusion, G-CSF (300 ug/d) by subcutaneous injection from day 0 until neutrophil count recovery to 2.0*10^9/L. | Shanghai Sixth People's Hospital; Shanghai Sixth People's Hospital, SHDC12010202 | high-risk MDS and AML transformed from MDS | | | | |
ChiCTR-TRC-10001209: A Phase III Study on optimizing treatment for elderly patients with acute myeloid leukemia |
|
|
| Completed | 4 | 500 | | HA±G-CSF for induction therapy ;AA±G-CSF for induction therapy ;consolidation therapy after complete response without autologous stem cell ;consolidation therapy after complete response supported by autologous stem cell | Hospital of Blood Diseases, Chinese Academy of Medical Sciences; Ministry of Health, China, Ministry of Health funding | Elderly patients with acute myeloid leukemia | | | | |
ChiCTR-TRC-14004836: A single-center, randomized, clinical study of a single dose of peg-rhG-CSF compared with daily rhG-CSF for supporting neutrophil recovery in acute myeloid leukemia patients. |
|
|
| Not yet recruiting | 4 | 60 | | peg-rhG-CSF ;rhG-CSF | Institute of Hematology &Blood Disease Hospital, Chinese Academy of Medical Sciences; Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, shiyao groups | acute myeloid leukemia | | | | |
2010-018752-27: Pharmacokinetics of anidulafungin (Ecalta ®) given intravenously as antifungal prophylaxis to recipients of an allogeneic haematopoietic stem cell transplant following myeloablative chemotherapy or patients receiving intensive chemotherapy for AML-MDS who are at high risk for developing invasive fungal disease |
|
|
| Ongoing | 4 | 20 | Europe | Ecalta, Ecalta | Radboud University Nijmegen Medical Centre | Pharmacokinetics of anidulafungin (Ecalta ®) given intravenously as antifungal prophylaxis to recipients of an allogeneic haematopoietic stem cell transplant following myeloablative chemotherapy or patients receiving intensive chemotherapy for AML-MDS who are at high risk for developing invasive fungal disease | | | | |
ChiCTR-IPR-17011884: Multi center clinical study of the efficacy and safety of rhTPO in treatment of thrombocytopenia after chemotherapy for acute myeloid leukemia |
|
|
| Completed | 4 | 85 | | subcutaneously injection of recombinant human TPO ;blank | Shandong provincial hospital; Shandong provincial hospital, self-paying | Acute myeloid leukemia | | | | |
2007-000806-64: Sequential treatment with Cytoreductive therapy & transplant for Relapsed/ Refractory Acute Myeloid Leukemia, High Risk Myelodysplasia,or other High Risk Myeloid Malignancies |
|
|
| Ongoing | 4 | 93 | Europe | Daunorubicin, Cytarabine Injection Solution 100mg/ml, Fludarabine, Methotrexate, Cyclophosphamide, | Barts Health NHS Trust | Relapsed/ Refractory Acute Myeloid Leukemia, High Risk Myelodysplasia,or other High Risk Myeloid Malignancies | | | | |
ChiCTR-TRC-11001482: A randomised clinical trial to compare the efficacy and safety of IA and intensive DA regimen as induction chemotherapy for de novo acute myeloid leukemia (AML) patients |
|
|
| Recruiting | 4 | 240 | | Idarubicin 12mg/ m2, intravenously administration daily for 3 days; Cytarabine 100mg/ m2,intravenously administration (mentain 24 hours) daily for 7days ;Daunorubicin 90mg/ m2, intravenously administration daily for 3 days; Cytarabine 100mg/ m2,intravenously administration (mentain 24 hours) daily for 7days | The First Affiliated Hospital of Soochow University; The First Affiliated Hospital of Soochow University, self-funded | acute myeloid leukemia (AML) | | | | |
ChiCTR-TRC-11001479: IA regimen as the induction chemotherapy in treatment of acute myeloid leukemia (AML): a multi-center, randomised clinical trial |
|
|
| Recruiting | 4 | 600 | | Idarubicin 8mg/ m2, intravenously administration daily for 3 days；Cytarabine 100mg/ m2,intravenously administration (mentain 24 hours) ;Idarubicin 10mg/ m2, intravenously administration daily for 3 days；Cytarabine 100mg/ m2,intravenously administration (mentain 24 hours) daily for 7days | the First Affiliated Hospital of Soochow University; the First Affiliated Hospital of Soochow University, self-funding | acute myeloid leukemia (AML) | | | | |
| Recruiting | 4 | 100 | | decitabine with low-dose idarubicin / cytarabine | 1st Affiliated Hospital, College of Medicine, Zhejiang University; 1st Affiliated Hospital, College of Medicine, Zhejiang University, research funding | AML envolving from MDS, MDS-RAEB | | | | |
2016-001223-31: Incidence of Invasive Fungal Disease in Patients receiving Immunosuppressive Therapy, Intensive Chemotherapy or Reduced Intensity Haematopoietic Stem Cell Transplantation on Posaconazole tablet Prophylaxis |
|
|
| Ongoing | 4 | 150 | Europe | Noxafil Gastro resistant tablets, Tablet, Noxafil® | King's College Hospital NHS Foundation Trust, Merck Sharp & Dohme Limited (MSD). | Aplastic Anaemia, Myelodysplastic syndromes, Acute Myeloid Leukaemia undergoing immunosuppression therapy, high dose chemotherapy or reduced intensity stem cell transplantation, Fungal infection as a result of immunosuppressive therapy, chemotherapy or stem cell transplantation., Diseases [C] - Blood and lymphatic diseases [C15] | | | | |
2013-001639-38: Verification of the effectiveness of adding granulocyte stimulating factor (G-CSF) to therapy patients with myelodysplastic syndrome (MDS) in high-risk disease. Ověření účinností přidání granulocyty stimulujícího faktoru (G-CSF) k dosavadní terapii nemocných s Myelodysplastickým syndromem (MDS) ve vysokém riziku onemocnění. |
|
|
| Ongoing | 4 | 135 | Europe | AZACITIDINE 25 mg/ml, FILGRASTIM, Powder for suspension for injection, Solution for injection/infusion, AZACITIDINE 25 mg/ml (Vidaza), FILGRASTIM 30 MU (60 MU/ml) FILGRASTIM 48 MU (96 MU/ml) | 1st Dep. of Medicine, General University Hospital (VFN) in Prague, 1st Dep. of Medicine, General University Hospital in Prague (VFN) | Patients with the diagnosis:HR-MDS, AML less than 30% myeloblasts and CMML II, who will be treated with AZA or AZA + G-CSF. Pacienti s diagnózou: HR-MDS, AML do 30% myeloblastů a CMML II, které budou lečeny terapii AZA nebo AZA + G-CSF., High risk Myelodysplastic sy., Acute myeloid leukemia less than 30% myeloblasts and chronic myelomonocytic leukemia II, who will be treated with therapy Azacitidine or Azacitidine + G-CSF. Myelodysplastický syndrom s vysokým riskem, Akutní myeloidní leukemie do 30 % myeloblastů a Chronická myelomonocytární leukemie II, budou léčeny terapii Azacitidinem nebo Azacitidinem + G-CSF., Diseases [C] - Cancer [C04] | | | | |
ChiCTR-ONC-14004688: Clinical Trial of Therapy with Thalidomide、Interferon and Interleukin-2 in Refractory/relapsed and Elderly Acute Myeloid Leukemia |
|
|
| Recruiting | 4 | 100 | | thalidomide，interferon，interleukin-2 | The Affiliated Cancer Hospital of Zhengzhou University/Henan Cancer Hospital; None, self-financed | refractory/relapsed and elderly acute myeloid leukemia | | | | |
ChiCTR-IPR-17012643: Subcutaneous vs intravenous administration of cytarabine during inductive chemotherapy in patients with de-novo acute myeloid leukemia: a prospective, multicenter, randomized controlled clinical trial |
|
|
| Recruiting | 4 | 240 | | Subcutaneous administration of cytarabine; Intravenous administration of cytarabine | The First affiliated Hospital, School of Medicine, Zhejiang University; The First affiliated Hospital, School of Medicine, Zhejiang University, Department of Hematology, The First affiliated Hospital, School of Medicine, Zhejiang University | Acute Myelogenous Leukemia | | | | |
ChiCTR-OPC-17011225: Efficacy and safety of DAC-CAG regimen: an open-label, prospective study in the primary elderly acute myeloid leukemia |
|
|
| Not yet recruiting | 4 | 80 | | DAC-CAG regimen | Department of Hematology, Tangdu Hospital, Fourth Military Medical University; Level of the institution：, This project is supported by the innovation and development fund of Tangdu Hospital | acute myeloid leukemia | | | | |
ChiCTR-OPC-16010166: Efficacy and safety of cladribine in combination with G-CSF, low-dose cytarabine and aclarubicin in patients with refractory/relapsed acute myeloid leukemia: a phase 2, single center, single arm study |
|
|
| Recruiting | 4 | 30 | | cladribine in combination with G-CSF, low-dose cytarabine and aclarubicin | Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center, Sun Yat-sen University Cancer Center | acute myeloid leukemia | | | | |
ChiCTR-TRC-14004196: Haplo-mismatch Donor Stem Cell Transplantation (SCT) versus Autologous SCT followed or not by maintenance therapy, for Patients with Acute Myeloid Leukemia (AML) in First Remission: A Chinese Randomized Multicenter Study |
|
|
| Recruiting | 4 | 212 | | undergo haplo-SCT ;undergo ASCT | Department of Hematology, the First Affiliated Hospital of Soochow University; Department of Hematology, the First Affiliated Hospital of Soochow University, Supported by Jiangsu Province’s Key Medical Center (ZX201102); National Public Health Grand Research Foundation (No.201202017); National High-tech R&D Program (863 Program) (2012AA02A505） | Acute Myeloid Leukemia | | | | |
ChiCTR-IIR-16008809: Homoharringtonine, aclacinomycin, cyctarabine and G-CSF (HCAG) regimen in the treatment of newly diagnosed elderly acute myeloid leukemia |
|
|
| Recruiting | 4 | 404 | | DA regimen ;HCAG regimen | Rui Jin hospital affiliated to Shanghai Jiaotong University School of Medicine, Shanghai Institute of Hematology; Rui Jin hospital affiliated to Shanghai Jiaotong University School of Medicine, Self-financing | Acute myeloid leukemia | | | | |
| Recruiting | 4 | 800 | | DAH induction+ATRA maintenance ;DAE induction+ATRA maintenance ;DAH induction+Ara-c maintenance ;DAE induction+Ara-c maintenance | Capital Medical University Beijing Children’s Hospital; Capital Medical University Beijing Children’s Hospital, Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding | pediatic acute myeloid leukemia | | | | |
ChiCTR1800015871: A clinical study of chidamide with FLAG (fludarabine+cytarabine+G-CSF) in the treatment of relapsed /refractory /first cycle induced non-remission acute myeloid leukemia |
|
|
| Recruiting | 4 | 10 | | Chidamide | Anhui Provincial Hospital; Anhui Provincial Hospital, chipscreen | Acute myeloid leukemia | | | | |
ChiCTR-OCH-14004731: Sorafenib in the treatment of AML patients with FLT3-ITD mutation: a cohort study |
|
|
| Recruiting | 4 | 100 | | Sorafenib ;Sorafenib ;Sorafenib ;Sorafenib ;Sorafenib | Department of Hematology, the First Affiliated Hospital of Soochow University; The First Affiliatd Hospital of Soochow University, None | Acute Myeloid Leukemia | | | | |
ChiCTR-OPC-17011617: A multicenter, prospective study for ultra low-dose decitabine in elderly patients with acute myelocytic leukemia or intermediate-high risk myelodysplastic syndrome |
|
|
| Not yet recruiting | 4 | 40 | | ultra low-dose decitabine | Central Hospital of Anshan City, The sixth clinical college of China Medical University; Central Hospital of Anshan City, The sixth clinical college of China Medical University, self-funding | acute myelocytic leukemia or myelodysplastic syndrome | | | | |
ChiCTR-OIC-16008952: The clinical study of initial induced remission failure in elderly patients with acute myeloid leukemia treated by IA in combination with decitabine |
|
|
| Not yet recruiting | 4 | 50 | | Decitabine+IA | Department of Hematology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine; Rui Jin hospital affiliated to Shanghai Jiaotong University School of Medicine, QILU pharmaceutical co.,Ltd. | Acute myeloid leukemia | | | | |
2019-004295-18: Fibrinogen and platelets in patients with acute myeloid leukaemia and thrombocytopenia |
|
|
| Ongoing | 4 | 20 | Europe | Concentrate for solution for infusion, Riastap | Aarhus University Hospital, Kræftens Bekæmpelse, CSL Behring | Bleeding i patients with acute myeloid leukemia, Bleeding i patients with acute myeloid leukemia, Diseases [C] - Blood and lymphatic diseases [C15] | | | | |
ChiCTR-IPR-16009917: Comparison of the curative efficacy and safety of allo-HSCT by using conditioning regiment of modified BUCY or CLAG combined with modified BUCY for refractory and relapsed patients with acute myelocytic leukemia: a sigle-center prospective randomized controlled clinical trial |
|
|
| Not yet recruiting | 4 | 116 | | Modified BUCY ;GLAG combined with BUCY | Aerospace Center Hospital; Aerospace Center Hospital, Beijing Municipal Science and Technology Commission | Relapse and Refractory Acute Myelocytic Leukemia | | | | |
ChiCTR-OPN-17012796: The single center, prospective clinical trial of low-dose Decitabine in the treatment of MDS/AML early relapse after allogeneic hematopoietic stem cell transplantation |
|
|
| Recruiting | 4 | 40 | | decitabine 5mg/m2 d1-5 | Department of Hematology, Xinqiao Hospital, Military Medical University; Xinqiao Hospital, Clinical Founding of Xinqiao Hospital | acute myeloid leukemia/Myelodysplastic syndrom | | | | |
ChiCTR-IPR-17011239: efficacy of prophylactic Levofloxacin for prevention of gut infection among de-novo AML patients: a randomised study |
|
|
| Recruiting | 4 | 120 | | prophylactic Levofloxacin ;no prophylactic antibiotics | Rui Jin hospital affiliated to Shanghai Jiaotong University School of Medicine, Shanghai Institute of Hematology; Rui Jin hospital affiliated to Shanghai Jiaotong University School of Medicine, self-financing | Acute myeloid leukemia | | | | |
ChiCTR1900023025: Clinical study for rhTPO in the treatment of thrombocytopenia after chemotherapy for acute leukemia |
|
|
| Not yet recruiting | 4 | 60 | | subcutaneously injection of recombinant human TPO ;blank | Anhui Provincial Hospital; Anhui Provincial Hospital, Self-financing | thrombocytopenia after chemotherapy for acute leukemia | | | | |
ChiCTR1800016691: Clinical research of Decitabine combined reduction FLAG regimen in the treatment of previously untreated high-risk and refractory or relapsed aged patients with acute myeloid leukemia |
|
|
| Not yet recruiting | 4 | 200 | | Decitabine combined reduction FLAG regimen ;Decitabine combined reduction FLAG regimen | Tianjin First Center Hospital; Tianjin First Center Hospital, Tianjin health department and Tianjin First Center Hospital | Acute myeloid leukemia | | | | |
NCT02926586: Fludarabine and Cytarabine Versus High-dose Cytarabine for CBF-AML |
|
|
| Completed | 4 | 68 | RoW | Fludarabine, Fludara, Cytarabine, Cytosar | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Acute Myeloid Leukemia, Core-Binding Factor | 08/20 | 07/24 | | |
ChiCTR1800020372: A multicenter, one-arm, open, prospective study for Decitabine combined with CHAG + cidabenamine in the treatment of relapsed/refractory acute myeloid leukemia (AML) |
|
|
| Recruiting | 4 | 50 | | Decitabine: 15mg/m2 intravenous d2-5 aclaramycin: 20mg/d intravenous administration qod d6, a total of 4-8 doses of harringtonine: 1mg/m2 intravenous administration qd d6-13 Cytarabine: 15mg/m2 Subcutaneous administration q12h d6-19 G-CSF: 300ug/d subcutaneous injection of d6--neutrophil recovery (suspended when WBC?20×109/L) Sidabenamine: d1 | Henan Cancer Hospital; Henan Cancer Hospital, Self-financing | Relapsed/refractory acute myeloid leukemia | | | | |
ChiCTR1800019603: An open label, multicenter, randomized controlled trial for decitabine in combination with half dose of CAG regimen (D-CAG regimen) in the treatment of MDS-EB and AML-MRC compared with CAG regimen |
|
|
| Recruiting | 4 | 140 | | Decitabine in combination with half dose of CAG regimen. ;CAG scheme | People's Hospital, Institute of hematology, Peking University; Peking University People's Hospital, Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | Myelodysplastic syndrome with excess blasts and Acute myeloid leukemia with myelodysplasia-related changes | | | | |
| Not yet recruiting | 4 | 70 | | GCSF 300ug d0-d5, Cladribine 5mg/m2, d1-5, cytarabine 2g/m2 qd, d1-5, homoharringtonine 2mg/m2d1-d5. ;GCSF 300ug d0-d5, azacytidine 100mg, d1-5, cedarabine 10mg qd, d1-28, cytarabine 10mg/m2 q12h, d3-9, homoharringtonine 1mg d3-d9. | Sichuan People's Hospital; Sichuan People's Hospital, Sichuan Science and Technology Department | Acute myeloid leukemia | | | | |
ChiCTR1900021030: Clinical research for decitabine in maintenance therapy for intermediate/high-risk myelodysplastic syndrome and elderly acute myeloid leukemia. |
|
|
| Not yet recruiting | 4 | 40 | | Decitabine | The First Hospital of Lanzhou University; The First Hospital of Lanzhou University, Company sponsorship and research funding. | Myelodysplastic syndrome, Elderly acute myeloid leukemia | | | | |
2021-001107-33: SARS-CoV-2 vaccination response in patients with haematologicaldisease Respons op SARS-Cov-2 vaccinatie in patiënten met een hematologischeziekte |
|
|
| Ongoing | 4 | 743 | Europe | Comirnaty, Suspension for injection in pre-filled injector, Comirnaty | MUMC, MUMC | multiple myeloma (including MGUS)chronic lymphocytic leukemia, chronic myeloid leukemia, acute myeloidleukemia, acute lymphocytic leukemia, non-Hodgkin lymphoma, Hodgkinlymphoma, myelodysplastic syndrome, myeloproliferative disease), haematological disease defined as:MM, MGUS, CLL, CML, AML, ALL, NHL, HL, MDS, MPN, Body processes [G] - Immune system processes [G12] | | | | |
ChiCTR1900022613: The clinical study for Dasatinib and Homoharringtonine in treating CBF AML |
|
|
| Not yet recruiting | 4 | 550 | | conventional intensive chemotherapy ;conventional intensive chemotherapy+HHT | Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai Institute of Hematology; Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Self-financing | Acute myeloid leukemia | | | | |
ChiCTR1900026095: Venetoclax + azacitidine combined with dose-adjusted HAG double induction therapy for relapsed/refractory acute myeloid leukemia |
|
|
| Not yet recruiting | 4 | 10 | | Venetoclax + Azacitidine +HAG | The People's Hospital of Jiaozuo City; The People's Hospital of Jiaozuo City, Beijing Medical Award Foundation | Relapse/Refractory Acute Myeloid Leukemia | | | | |
ChiCTR1800016423: A non-interventional, observational post-marketing registry of Vidaza (subcutaneous azacitidine) in patients with intermediate-2 and high-risk myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia with 20-30 % blasts and multi-lineage dysplasia in China |
|
|
| Recruiting | 4 | 300 | | Vidaza | Tianjin Hematonosis Hospital; Tianjin Hematonosis Hospital, Celgene Pharmaceutical (Shanghai) Co. Ltd | Intermediate-2 and high-risk myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia with 20-30 % blasts and multi-lineage dysplasia | | | | |
ChiCTR1900023368: Decitabine combined with conventional chemotherapy improves outcome in pediatric AML: a randomized controlled trial |
|
|
| Recruiting | 4 | 40 | | Decitabine and conventional chemotherapy ;conventional chemotherapy | The Seventh Affiliated Hospital, Sun Yat-sen University; The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen Manicipal Health Commission | Acute myeloid leukemia | | | | |
2019-001585-15: PTX3 genetically stratified randomized double-blinded allocation event-driven clinical trial for antifungal prophylaxis in patients with acute myeloid leukemia Etude d’allocation génétique de la prophylaxie antifongique chez les patients traités pour une leucémie aiguë myéloïde |
|
|
| Ongoing | 4 | 105 | Europe | Solution for infusion, Powder for solution for infusion, Capsule, Tablet, Noxafil, Diflucan | Centre Hospitalier Universitaire Vaudois, Swiss National Science Foundation | Invasive mold infections leucémie aigue myéloïde, Invasive mold infections leucémie aigue myéloïde, Not possible to specify | | | | |
ChiCTR2000037928: Clinical efficacy and MRD monitoring of relapse prevention of decitabine containing induction chemotherapy in de novo AML: a multi-center, prospective, randomized controlled study |
|
|
| Recruiting | 4 | 122 | | decitabine+IA chemotherapy ;IA chemotherapy | Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of science and technology; Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of science and technology, Self finance | Acute myeloid leukemia | | | | |
| Recruiting | 4 | 40 | RoW | Cyclosporine Ophthalmic, Ikervis | Singapore Eye Research Institute | Leukemia (Both ALL and AML), MDS-EB-1 | 08/22 | 12/22 | | |
ChiCTR2100045330: Clinical study of Bcl-2 inhibitors combined with azacytidine and chemotherapy in elderly patients with previously untreated acute myeloid leukemia (AML) |
|
|
| Recruiting | 4 | 30 | | Induced remission: Venecola + azacabine; Consolidation therapy (option A or B according to patient's wishes) : Option A (Vinecola + cytarabine + clatribin; Venecola + cytarabine) followed; Plan B (Vinecra + Idabicin + cytarabine; Venecola + cytarabine) followed; Maintenance period: azacytidine. | The First Hospital of Lanzhou University; The First Hospital of Lanzhou University, Sponsored by Hanhui Pharmaceutical Co. Ltd | acute myeloid leukemia | | | | |
ChiCTR2100051018: The efficacy and safety of Venetoclax plus Azacitidine and LDAC in the treatment of relapsed and refractory acute myeloid leukaemia patients: Prospective, single arm, multicenter, phase 2 clinical study |
|
|
| Completed | 4 | 31 | | VAA regimen | the First Affiliated Hospital of Zhejiang University School of Medicine; the First Affiliated Hospital of Zhejiang University School of Medicine, self-funded | Acute myeloid leukemia | | | | |
NCT03873311: Azacytidine + HAG Regimen vs. Azacytidine for Elderly Patients With Newly Diagnosed Myeloid Malignancy |
|
|
| Recruiting | 4 | 114 | RoW | Azacytidine, HAG Regimen, Azacytidine, HAG Regimen (HHT Cytarabine G-CSF), Azacytidine | Shenzhen Second People's Hospital | Acute Myeloid Leukaemia; Myelodysplastic Syndromes;Chronic Myelomonocytic Leukemia | 12/22 | 06/23 | | |
| Recruiting | 4 | 200 | | CAGM ;CAG | The First Afliated Hospital of Soochow University; The First Afliated Hospital of?Soochow University, self-raised | Relapsed/Refractory Acute Myelomonocytic or Monocytic Leukemia | | | | |
ChiCTR1800019827: Maintenance treatment of decitabine without bone marrow toxicity for elderly patients with acute myeloid leukemia |
|
|
| Recruiting | 4 | 106 | | Decitabine without bone marrow toxicity for Maintenance treatment ;Routine treatment without dicitabine | Department of Hematology, Xinqiao Hospital; Department of Hematology, Xinqiao Hospital, The clinical research project of Xinqiao Hospital of Army military medical university | elderly acute myeloid leukemia | | | | |
| Recruiting | 4 | 600 | | Ara-c+6-TG ;ATRA+RIF | Capital Medical University Beijing Children's Hospital; Capital Medical University Beijing Children's Hospital, self-raised | pediatic acute myeloid leukemia | | | | |
ChiCTR2100054356: Clinical Efficacy of Low-Dose Venetoclax Combinated with Posaconazole in Acute Myeloid Leukemia Patients: Evaluation of Dose Adjustments Guided by Venetoclax Blood Concentration |
|
|
| Not yet recruiting | 4 | 60 | | oral venetoclax 100mg/d combined with posaconazole200mg tid ;oral venetoclax 400mg/d | Chengdu Third People's Hospital; Chengdu Third People's Hospital, Personal research funds | acute myeloid leukemia | | | | |
| Recruiting | 4 | 50 | | venetocax ;venetocax ;venetocax ;venetocax | Beijing Children's Hospital, Capital Medical University; Beijing Children's Hospital, Capital Medical University, Capital Health Development Research Project (No. 2022-1-20191) | Acute myeloid leukemia (AML) | | | | |
ChiCTR2000029393: A clinical study to evaluate the efficacy and safety of azacitidine in maintenance therapy in elderly patients with acute myeloid leukemia (≥60 years of age) |
|
|
| Not yet recruiting | 4 | 164 | | Azacitidine ;Conventional chemotherapy | The First Afflilated Hospital, Collegue of Medicine, College of medicine, Zhejiang University; The First Afflilated Hospital, Collegue of Medicine, Zhejiang University, funding | Acute myeloid leukemia | | | | |
ChiCTR2000038340: Single-arm, open, multicenter clinical study of Cladribine combined with HAG regimen in the treatment of relapsed/refractory pediatric acute myeloid leukemia |
|
|
| Recruiting | 4 | 157 | | Cladribine combined with HAG regimen | Institute of Hematology, Blood Disease Hospital, Chinese Academy of Medical Sciences; Institute of Hematology, Blood Disease Hospital， Chinese Academy of Medical Sciences, Not stated | Relapsed/refractory pediatric acute myeloid leukemia | | | | |
ChiCTR2000032256: Clinical study for GHA combined with Azacitidine regimen in the treatment of elderly patients with acute myeloid leukemia |
|
|
| Recruiting | 4 | 65 | | GHA+AZA regimen | The First Affiliated Hospital of Zhejiang University Medical College; The First Affiliated Hospital of Zhejiang University Medical College, Self-faised funds | Acute myeloid leukemia | | | | |
ChiCTR2000035310: A clinical study of interferon-α-2b in maintenance therapy of low risk acute myeloid leukemia |
|
|
| Recruiting | 4 | 31 | | Interferon-α-2b | People's Hospital, Institute of Hematology, Peking University; Peking University People's Hospital, National Clinical Research Center for Hematolagic Disease, Peking University People's Hospital | low risk acute myeloid leukemia | | | | |
ChiCTR2000034927: Clinical Study on the Treatment of Elderly Acute Myelocytic Leukemia and Myelodysplastic Syndrome with Azacytidine Combined PD-1 Monoclonal Antibody |
|
|
| Recruiting | 4 | 30 | | Azacytidine combined PD-1 Monoclonal Antibody ;Azacytidine | West China Hospital Shangjinnanfu Hospital; West China Hospital Shangjinnanfu Hospital, uninvolved | Acute Myelocytic Leukemia / Myelodysplastic Syndrome EB1/2 | | | | |
ChiCTR2100049606: A multicenter, open, prospective controlled clinical study comparing the efficacy and safety of CLAG regimen combined with modified BUCY and modified BUCY regimen in allogeneic hematopoietic stem cell transplantation in the treatment of relapsed and refractory AML |
|
|
| Not yet recruiting | 4 | 298 | | GLAG combined with modified BUCY ;Modified BUCY | Aerospace Center Hospital; Aerospace Center Hospital, Aerospace Medical and Health Technology Group Co., Ltd. Scientific Research Fund | Relapse and Refractory Acute Myelocytic Leukemia | | | | |
ChiCTR2100050154: Clinical study of azacytidine combined with low-dose venetoclax in the treatment of untreated fragile senile AML |
|
|
| Not yet recruiting | 4 | 30 | | Azacytidine plus low dose venetoclax | Beijing Hospital; Beijing Hospital, Raise independently | acute myeloid leukemia | | | | |
ChiCTR2100050627: Clinical study of azacytidine combined with low-dose venetoclax in the treatment of relapse / refractory senile acute myeloid leukemia |
|
|
| Not yet recruiting | 4 | 20 | | azacytidine plus low dose venetoclax | Beijing Hospital; Beijing Hospital, self-funded | acute myeloid leukemia | | | | |
ChiCTR2200060047: A Prospective, Single-center, Exploratory Study of Low-Dose Cytarabine, Mitoxantrone Liposome Combined with Granulocyte Colony Stimulating Factor in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia |
|
|
| Recruiting | 4 | 12 | | Cytarabin+ Mitoxantrone Liposome+Granulocyte Colony Stimulating Factor | The First Affiliated Hospital, College of Medicine, Zhejiang University; The First Affiliated Hospital, College of Medicine, Zhejiang University, CSPC OUYI PHARMACEUTICAL CO., LTD. | Relapsed or Refractory Acute Myeloid Leukemia | | | | |
NCT03026842: Decitabine Versus Conventional Chemotherapy for Maintenance Therapy of Acute Myeloid Leukemia With t(8;21) |
|
|
| Active, not recruiting | 4 | 180 | RoW | Decitabine, Daunorubicin, Cytarabine, Mitoxantrone, Cytarabine, Aclacinomycin, Cytarabine | The First Hospital of Jilin University, The Second Affiliated Hospital of Dalian Medical University, Second Hospital of Jilin University, Jilin University | Acute Myeloid Leukemia | 12/23 | 10/24 | | |
ChiCTR2100046789: A prospective, multi-center, non-intervention, observational clinical study of idarubicin hydrochloride for injection combined with cytarabine low-dose chemotherapy regimen as consolidation therapy for elderly patients with acute myelogenous leukemia (AML) |
|
|
| Recruiting | 4 | 70 | | Nil | Department of Hematology, Shanxi Provincial Cancer Hospital; Shanxi Provincial Cancer Hospital, None | Acute myelogenous leukemia | | | | |
ChiCTR2200061294: A Prospective, Multicenter, Observational Clinical Study of the Pharmacokinetics and Pharmacodynamics of Venetoclax in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome |
|
|
| Not yet recruiting | 4 | | | | The First Affiliated Hospital of Zhejiang University Medical College; The First Affiliated Hospital of Zhejiang University Medical College, Research funding | myelodysplastic syndromes, acute myeloid leukemia | | | | |
ChiCTR2100042418: Clinical research for azacitidine combined with low-dose dasatinib in maintenance treatment of Acute Myeloid Leukemia |
|
|
| Recruiting | 4 | 30 | | Azacitidine combined with low-dose dasatinib ;Azacitidine | The First Hospital of Lanzhou University; The First Hospital of Lanzhou University, Sponsored by charitable foundation | acute myeloid leukemia | | | | |
ChiCTR2200060080: Dose-escalation clinical study of mitoxantrone hydrochloride liposome injection combined with cladribine, cytarabine and granulocyte colony-stimulating factor in the treatment of relapsed or refractory acute myeloid leukemia |
|
|
| Recruiting | 4 | 18 | | Cladribine+Cytarabine+Granulocyte colony-stimulating factor+Mitoxantrone liposome | The Second Affiliated Hospital of the Army Medical University of the PLA; The Second Affiliated Hospital of the Army Medical University of the PLA, NA | Relapsed or Refractory Acute Myeloid Leukemia | | | | |
| Recruiting | 4 | 118 | RoW | Venetoclax, Allogeneic transplant | He Huang | Acute Myeloid Leukemia | 12/27 | 02/28 | | |
NCT05144243: Study to Assess Adverse Events and Change in Disease State of Oral Venetoclax in Combination With Subcutaneous (SC) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy in China |
|
|
| Active, not recruiting | 4 | 44 | RoW | Venetoclax, ABT-199, GDC-0199, Venclexta, Azacitidine | AbbVie, Genentech, Inc. | Acute Myeloid Leukemia (AML) | 07/24 | 07/24 | | |
ChiCTR2200062540: Clinical study of allogeneic umbilical cord blood transplantation using CLAG-based conditioning regimen in the treatment of pediatric high-risk acute leukemia |
|
|
| Not yet recruiting | 4 | 20 | | To carry out allogeneic umbilical cord blood stem cell transplantation with CLAG + Bu/CY as conditioning regimen for the treatment of high-risk acute leukemia in children | Institute of Hematology, Blood Disease Hospital, Chinese Academy of Medical Sciences; Institute of Hematology, Blood Disease Hospital, Chinese Academy of Medical Sciences, Unit self-raised | pediatric high-risk acute leukemia | | | | |
NCT05252585: A Phase IV Study of Safety and Efficacy of Everolimus in Taiwanese Patients With Tuberous Sclerosis Complex Who Have Renal Angiomyolipoma (TSC-AML) |
|
|
| Recruiting | 4 | 10 | RoW | Everolimus, RAD001 | Novartis Pharmaceuticals | Renal Angiomyolipoma | 02/26 | 02/26 | | |
REMAIN1, NCT06370000: Oral Azacitidine in Transplant-Eligible Patients With Acute Myeloid Leukemia (AML) Suffering From Health-Inequality |
|
|
| Recruiting | 4 | 12 | US | Oral Azacitidine | Virginia Commonwealth University | Acute Myeloid Leukemia | 01/27 | 01/29 | | |
ChiCTR2100052486: Single arm, multicenter, prospective clinical study of azacytidine in maintenance therapy of AML and MDS |
|
|
| Not yet recruiting | 4 | 80 | | Azacytidine maintenance therapy | Huadong Hospital Affiliate to Fudan University; Huadong Hospital Affiliate to Fudan University, BeiGene Biomedical Technology Co., Ltd | MDS/AML | | | | |
ChiCTR2200063308: A Prospective, Single-center and Exploratory Study of Hartaxidine and Cytarabine Combined with Mitoxantrone Liposome in The Treatment of Relapsed and Refractory Acute Myeloid Leukemia |
|
|
| Not yet recruiting | 4 | 65 | | hartaxidine and cytarabine combined with mitoxantrone liposome | Tianjin Medical University General Hospital; Tianjin Medical University General Hospital, Beijing Cancer Prevention&Treatment Society | Relapsed or Refractory Acute Myeloid Leukemia | | | | |
ChiCTR2000034990: Prospective, randomized, single-center, controlled trial for dasatinib maintenance therapy after autologous hematopoietic stem cell transplantation in CBF-AML |
|
|
| Recruiting | 4 | 60 | | Dasatinib 100mg po qd ;observation | Affiliated Hospital of Southwest Medical University; Affiliated Hospital of Southwest Medical University, pharmaceutical factory | core-binding factor acute myeloid leukemia | | | | |
ChiCTR2200060085: Phase I Dose Escalation Study of Mitoxantrone Hydrochloride Liposome Injection Combined with Cytarabine and Etoposide in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia |
|
|
| Recruiting | 4 | 18 | | Mitoxantrone Liposome + Cytarabine + Etoposide | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, CSPC OUYI PHARMACEUTICAL CO., LTD. | Relapsed or Refractory Acute Myeloid Leukemia | | | | |
ChiCTR2300071651: Exploratory study on Selinexor combined with chemotherapy in the treatment of relapsed refractory AML |
|
|
| Recruiting | 4 | 30 | | Selinexor combined with chemotherapy (HMA, HMA-HAG, FLAG) | Zhangzhou Municipal Hospital Affiliated to Fujian Medical University; Zhangzhou Municipal Hospital Affiliated to Fujian Medical University, None | AML | | | | |
ChiCTR2200056635: A prospective clinical study of the safety and efficacy of the combination of decitabine, GM-CSF, and PD-1 inhibitor in the treatment of elderly patients (≥65 years old) with acute myeloid leukemia (AML) |
|
|
| Recruiting | 4 | 30 | | the combination of decitabine, GM-CSF, and PD-1 inhibitor | Affiliated Hospital of Xuzhou Medical University; Affiliated Hospital of Xuzhou Medical University, self-financing | acute myeloid leukemia | | | | |
ChiCTR2300067964: Clinical study on pharmacokinetics of Mitoxantrone hydrochloride liposome injection combined with cytarabine in children with newly diagnosed acute myeloid leukemia |
|
|
| Not yet recruiting | 4 | 8 | | Mitoxantrone liposome combined with cytarabine ± etoposide | Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, CSPC Ouyi Pharmaceutical Co., Ltd. | Children with newly diagnosed acute myeloid leukemia | | | | |
NCT06041529: Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients with Essential Hypertension |
|
|
| Recruiting | 4 | 250 | RoW | Telmisartan/Amlodipine/Chlorthalidone 40/5/12.5 mg, Truset 40/5/12.5mg, Telmisartan/Amlodipine/Hydrochlorothiazide 40/5/25 mg, Twynsta 40/5 mg, Dichlozid 25 mg | Yuhan Corporation | Essential Hypertension | 06/25 | 10/25 | | |
ChiCTR2200067172: Efficacy and Safety of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Acute Myeloid Leukemia: a Multicenter, Non-Interference, Two-Way Cohort Real World Study |
|
|
| Not yet recruiting | 4 | 200 | | mitoxantrone hydrochloride liposome | Institute of Hematology&Oncology, Harbin First Hospital; Institute of Hematology&Oncology, Harbin First Hospi, CSPC Ouyi Pharmaceutical Co., Ltd. | Acute Myeloid Leukemia | | | | |
ChiCTR2200062462: Prospective, single arm, multicenter clinical study of veneclax combined with azacitidine sequential unrelated umbilical cord blood micro transplantation in treatment of elderly acute myeloid leukemia |
|
|
| Recruiting | 4 | 28 | | Veneclax combined with azacitidine sequential unrelated umbilical cord blood micro transplantation | The First Affiliated Hospital, College of Medicine, Zhejiang University; The First Affiliated Hospital, College of Medicine, Zhejiang University, Self-raised | Acute myeloid leukemia | | | | |
ChiCTR2200058557: A prospective, multicentre, randomised, controlled study of Venetoclax and Azacitidine versus Azacitidine as maintenance therapy after allogeneic stem cell transplantation in patients with high risk of recurrence of MDS, CMML and AML |
|
|
| Recruiting | 4 | 118 | | Venetoclax and Azacitidine Combination ;Azacitidine | Blood Diseases Hospital, Institute of Hematology, Chinese Academy of Medical Sciences; Blood Diseases Hospital, Institute of Hematology, Chinese Academy of Medical Sciences, None | Myelodysplastic syndrome (MDS)/chronic monocytic leukemia (CMML)/acute myeloid leukemia (AML) | | | | |
| Recruiting | 4 | 60 | | CLAG in conjunction with PLD | Department of Hematology, Second Affiliated Hospital of Anhui Medical University; The Second Affiliated Hospital of Anhui Medical University, Self-funded by the department | Acute myeloid leukemia | | | | |
| Recruiting | 4 | 160 | Europe | Prevenar13 Pneumo-23 | Poitiers University Hospital | Vaccine, Streptococcus Pneumoniae, Acute Myeloid Leukemia, Lymphoma, Non-Hodgkin | 06/26 | 06/26 | | |
ChiCTR2400084836: A cohort study of azacitidine combined with different dosages of venetoclax in the treatment of elderly patients with AML unsuitable for chemotherapy |
|
|
| Not yet recruiting | 4 | 320 | | None; None | Beijing Hospital; Beijing Hospital, Beijing Hospital Clinical Research "Navigation Aid" Special Project | AML | | | | |
ChiCTR2200057563: Multicenter, prospective, randomized, controlled study of the efficacy and safety of claritrebin regimens in reinduction therapy in newly treated children with AML (non-M3) |
|
|
| Recruiting | 4 | 64 | | IAE ;C+HAG | Institute of Hematology, Blood Disease Hospital, Chinese Academy of Medical Sciences; Institute of Hematology, Blood Disease Hospital, Chinese Academy of Medical Sciences, Not stated | pediatric acute myeloid leukemia | | | | |
ChiCTR2300076685: Efficacy and safety of serenixol combined with the priming regimen in the treatment of recurrent and refractory AML and high risk MDS with vineclavone resistance: a multicenter, single-arm, prospective clinical study |
|
|
| Recruiting | 4 | 96 | | Serenixol, Dexcitabine, Cytarabine, Aclamycin, Homoharringtonine, Demethoxydaunorubicin, Granulocyte colony stimulating factor | Hebei Provincial Hospital of Traditional Chinese Medicine; Hebei Provincial Hospital of Traditional Chinese Medicine, None | Myelodysplastic syndrome & Acute myeloid leukemia | | | | |
ChiCTR2300072012: Prospective single-arm clinical study of TBC as conditioning regimen for haplo-identical hematopoietic stem cell transplantation in refractory / relapsed acute myeloid leukemia |
|
|
| Recruiting | 4 | 100 | | Conditioning regimen consisted of thiotepa, cyclophosphamide and bulsulfan (TBC) | Soochow Hopes Hematonosis Hospital; Soochow Hopes Hematonosis Hospital, None | Refractory / relapsed acute myeloid leukemia | | | | |
ChiCTR2300077623: Clinical study of chemotherapy-free or low-dose chemotherapy regimen containing Selinexor in the treatment of relapsed/refractory acute myeloid leukemia |
|
|
| Recruiting | 4 | 68 | | Selinexor-containing Chemotherapy-free or Low-dose Chemotherapy Regimens | Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology; Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Self financed | Relapsed/Refractory Acute Myeloid Leukemia | | | | |
ChiCTR2300077634: Clinical study of selinexor-containing regimens in post-transplant AML patients who molecular relapse but failed after first-line preemptive treatment |
|
|
| Recruiting | 4 | 68 | | Selinexor-containing Chemotherapy-free or Low-dose Chemotherapy Regimens | Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology; Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Self-financed | Acute Myeloid Leukemia | | | | |
ChiCTR2300069328: Prospective, Multicenter, Single-Arm Clinical Study of Cladribine Combined with HAG Regimen in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia |
|
|
| Not yet recruiting | 4 | 108 | | Cladribine + HAG | The First Affiliated Hospital of Army Medical University (Southwest Hospital); The First Affiliated Hospital of Army Medical University (Southwest Hospital), NA | Relapsed/refractory acute myeloid leukemia | | | | |
ChiCTR2300076031: Efficacy and safety of Decitabine in combination with Venecola and Selinisol (DVS) in the treatment of unfit and newly diagnosed AML and MDS, relapsed refractory AML and high-risk MDS: a multicenter, single-arm, prospective clinical study |
|
|
| Not yet recruiting | 4 | 96 | | Decitabine , Venecra and Selinisol | The Second Hospital of Hebei Medical University; The Second Hospital of Hebei Medical University, None | Myelodysplastic syndrome & Acute myeloid leukemia | | | | |
ChiCTR2100041866: The clinical study of Pre-chemotherapy recombinant human thrombopoietin to reduce chemotherapy-induced thrombocytopenia of acute myeloid leukemia patients |
|
|
| Recruiting | 4 | 64 | | pre-chemo TPO in the first cycle of two intensive chemotherapy ;pre-chemo TPO in the second cycle of two intensive chemotherapy | The First Affiliated Hospital of Anhui Medical University; The First Affiliated Hospital of Anhui Medical University, self-raised | Acute myeloid leukemia | | | | |
ChiCTR2300070019: Prospective, multicenter and exploratory study of mitoxantrone hydrochloride liposome injection combined with cytarabine in the treatment of primary secondary acute myeloid leukemia in the elderly patients |
|
|
| Not yet recruiting | 4 | 60 | | mitoxantrone hydrochloride liposome + cytarabine | Ruijin Hospital, Shanghai Jiaotong University School of Medicine; Ruijin Hospital, Shanghai Jiaotong University School Of Medicine, CSPC Ouyi Pharmaceutical Co., Ltd. | Acute Myeloid Leukemia | | | | |
ChiCTR2300069327: Prospective, Multicenter, Single-Arm Clinical Study of Venetoclax Combined with Cladribine + HAG Regimen in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia |
|
|
| Not yet recruiting | 4 | 106 | | Venetoclax Combined With Cladribine + HAG | The First Affiliated Hospital of Army Medical University (Southwest Hospital); The First Affiliated Hospital of Army Medical University (Southwest Hospital), NA | Relapsed/refractory acute myeloid leukemia | | | | |
ChiCTR2200061524: Clinical study of venetoclax combined with chemotherapy in the treatment of newly diagnosed acute myeloid leukemia |
|
|
| Recruiting | 4 | 60 | | Oral venetoclax ;Without venetoclax | Handan Central Hospital; Handan Central Hospital, Self-paying | Acute myeloid leukemia | | | | |
| Not yet recruiting | 4 | 816 | | The combination of targeted therapy and chemotherapy was applied in the treatment of reduction of volume, induction therapy, consolidation therapy and maintenance therapy, and venetoclax combined with RIF in maintenance period; The combination of targeted therapy and chemotherapy was applied in the treatment of reduction of volume, induction therapy, consolidation therapy and maintenance therapy, and only Venetoclax in maintenance period | Beijing Children's Hospital, Capital Medical University; Beijing Children's Hospital, Capital Medical University, self-raised | Acute myeloid leukemia in children | | | | |
ChiCTR2400086291: A prospective, multi-center clinical study of mitoxantrone hydrochloride liposome injection combined with cladribine, cytarabine and granulocyte colony-stimulating factor in the treatment of relapsed and refractory acute myeloid leukemia |
|
|
| Not yet recruiting | 4 | 50 | | Cladribine+Cytarabine+Granulocyte colony-stimulating factor+Mitoxantrone liposome | The Second Affiliated Hospital of the Army Medical University of the PLA; The Second Affiliated Hospital of the Army Medical University of the PLA | Relapsed or Refractory Acute Myeloid Leukemia | | | | |
